IP Library › Granted Patent US 7,560,471
Granted Patent B2
US 7,560,471 · App. 10/515,407 · Granted Jul 14, 2009

Indolylpiperidine derivatives as potent antihistaminic and antiallergic agents

Assignee: Laboratorios Almirall S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,560,471
App. No.
10/515,407
Granted
Jul 14, 2009
Kind
B2
Abstract

This invention is directed to new potent and selective antagonists of H 1 histamine receptors having the general formula I to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy as antiallergic agents.

Claims (40)

1. A compound of formula I

wherein:

R 1 represents an alkyl, alkenyl, alkoxyalkyl or cycloalkylalkyl group;

R 2 represents a hydrogen or halogen atom; and

wherein the methoxy group substituting the benzoic acid is in position ortho with respect to the carboxy groups and in position para with respect to the carbon atom that is bound to the indolylpiperidine moiety;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein R 1 is chosen from ethyl, n-propyl, n-butyl, methoxymethyl, methoxyethyl, ethoxyethyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylethyl, allyl, 2-propenyl, 2-propoxyethyl and 3-methoxypropyl.

3. A compound according to claim 2 , wherein R 1 is methoxyethyl, ethoxyethyl, butyl, cyclopropylmethyl or allyl.

4. A compound according to claim 1 , wherein R 2 is hydrogen, fluorine or chlorine.

5. A compound according to claim 4 , wherein R 2 is hydrogen, fluorine or chlorine.

6. A compound according to claim 1 , chosen from:

5-{4-[1-(2-ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid;

2-methoxy-5-{4-[1-(2-methoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-benzoic acid;

5-[4-(1-butyl-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

5-{4-[1-(2-ethoxyethyl)-6-fluoro-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid;

5-{4-[6-fluoro-1-(2-methoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid;

5-[4-(1-butyl-6-fluoro-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

5-[4-(5-bromo-1-propyl-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

3-[4-(5-chloro-1-ethyl-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

3-[4-(1-cyclopropylmethyl-5-fluoro-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

5-[4-(5-chloro-1-cyclohexylmethyl-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

2-methoxy-5-{4-[1-(2-propoxyethyl)-1H-indol-3-yl]-piperidin-1-ylmethyl}-benzoic acid;

3-{4-[5-bromo-1-(3-methoxypropyl)-1H-indol-3-yl]-piperidin-1-ylmethyl}-2-methoxybenzoic acid;

3-[4-(1-allyl-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

3-[4-(1-allyl-6-fluoro-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

5-{4-[5-chloro-1-(2-propenyl)-1H-indol-3-yl]-piperidin-1-ylmethyl}-2-methoxybenzoic acid;

5-[4-(1-cyclopentylmethyl-6-fluoro-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

3-{4-[6-fluoro-1-methoxymethyl-1H-indol-3-yl]-piperidin-1-ylmethyl}-2-methoxybenzoic acid;

3-{4-[1-cyclopropylethyl-1H-indol-3-yl]-piperidin-1-ylmethyl}-2-methoxybenzoic acid;

3-{4-[5-chloro-1-(2-methoxyethyl)-1H-indol-3-yl]-piperidin-1-ylmethyl}-2-methoxybenzoic acid; and

3-{4-[1-(2-ethoxyethyl)-5-fluoro-1H-indol-3-yl]-piperidin-1-ylmethyl}-2-methoxybenzoic acid.

7. A compound according to claim 6 , chosen from:

5-{4-[1-(2-ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid;

2-methoxy-5-{4-[1-(2-methoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-benzoic acid;

5-[4-(1-butyl-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid;

5-{4-[1-(2-ethoxyethyl)-6-fluoro-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid;

5-{4-[6-fluoro-1-(2-methoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid; and

5-[4-(1-butyl-6-fluoro-1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxybenzoic acid.

8. A pharmaceutical composition comprising an effective amount of at least one compound as defined in claim 1 , and at least one pharmaceutically acceptable diluent or carrier.

9. A method for treating a subject afflicted with a pathological condition or disease is chosen from bronchial asthma, allergic rhinitis, conjunctivitis, dermatitis, and urticaria comprising administering to said subject an effective amount of at least one compound as defined in claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2007
From: ALMIRALL PRODESFARMA S.A.
To: LABORATORIOS ALMIRALL, S.A.
Reel/Frame 018786/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2005
From: FONQUERNA POU, SILVIA; PAGES SANTACANA, LUIS MIGUEL
To: ALMIRALL PRODESFARMA S.A.
Reel/Frame 016760/0550 →
Priority Claims (1)
ES 200201226 · May 29, 2002 · national
Continuity (1)
Related Publication 20060094879A1 · May 4, 2006